Dr. Reddy's Laboratories Limited Stocks

Established in 1984 and headquartered in Hyderabad, India, Dr. Reddy's Laboratories Limited functions as a fully integrated global pharmaceutical entity. Its business is structured into several core divisions. The Global Generics segment is responsible for the production and distribution of prescription and over-the-counter finished pharmaceutical products, marketed either under their own brand names or as generic versions therapeutically equivalent to branded formulations, also encompassing biologics. The Pharmaceutical Services and Active Ingredients (PSAI) division manufactures and supplies active pharmaceutical ingredients (APIs) and intermediates, which are fundamental components for finished drugs, alongside offering contract research services and custom production of APIs and steroids. The Proprietary Products segment is dedicated to the research and development of unique and differentiated drug formulations. Furthermore, its "Others" segment focuses on developing treatments for oncology and inflammatory conditions. The company's therapeutic reach spans numerous areas including gastro-intestinal, cardiovascular, anti-diabetic, dermatological, oncology, respiratory, stomatological, urological, and nephrological health. Dr. Reddy's also maintains a strategic collaboration with Curis, Inc., centered on the discovery, development, and commercialization of small molecule antagonists for immuno-oncology and precision oncology applications.